BioSight
Companies
Avalo Therapeutics, Inc. logo

AVTX

NASDAQWAYNE, PA
Avalo Therapeutics, Inc.

Avalo Therapeutics is a clinical-stage biotechnology company focused on developing IL-1-based monoclonal antibody treatments for immune-mediated inflammatory diseases. The company's lead product candidate, abdakibart (AVTX-009), is a humanized anti-IL-1 monoclonal antibody currently in Phase 2 clinical development for hidradenitis suppurativa, with topline data expected in the second quarter of 2026. Avalo is also exploring additional indications for abdakibart and pursuing a strategy of in-licensing complementary compounds targeting immune-mediated inflammatory diseases.

Price history not yet available for AVTX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar